Results 101 to 110 of about 5,690,964 (274)

The Reversing and Molecular Mechanisms of miR-503 on the Drug-resistance 
to Cisplatin in A549/DDP Cells

Chinese Journal of Lung Cancer, 2014
Background and objective Cisplatin-resistance in lung cancer cells is general in clinic, hence it is significant to investigate the mechanisms of cisplatin-resistant and develop new methods of reversing drug-resistance.
Yi WU, Lili GUO, Jinghao LIU, Renwang LIU, Minghui LIU, Jun CHEN   +5 more
doaj   +1 more source

Inhibition of acyl‐CoA synthetase long‐chain isozymes decreases multiple myeloma cell proliferation and causes mitochondrial dysfunction

Molecular Oncology, EarlyView.
Triacsin C inhibition of the acyl‐CoA synthetase long chain (ACSL) family decreases multiple myeloma cell survival, proliferation, mitochondrial respiration, and membrane potential. Made with Biorender.com. Multiple myeloma (MM) is an incurable cancer of plasma cells with a 5‐year survival rate of 59%.
Connor S. Murphy, Heather Fairfield, Victoria E. DeMambro, Samaa Fadel, Carlos A. Gartner, Michelle Karam, Christian Potts, Princess Rodriguez, Ya‐Wei Qiang, Habib Hamidi, Xiangnan Guan, Calvin P. H. Vary, Michaela R. Reagan   +12 more
wiley   +1 more source

Consensus of Chinese Experts on Medical Treatment of Advanced Lung Cancer 
in the Elderly (2022 Edition)

Chinese Journal of Lung Cancer, 2022
Lung Cancer Specialty Committee of Chinese Elderly Health Care Association, Lung Cancer Specialty Committee of Beijing Cancer Society   +1 more
doaj   +1 more source

Durvalumab after chemoradiotherapy in stage III non-small cell lung cancer.

Journal of Thoracic Disease, 2018
Immune Check Point inhibitors (ICIs) have demonstrated efficacy in advanced stage solid tumors including non-small cell lung cancer (NSCLC), CTLA4, programmed cell death-1 (PD-1) and PD-1 ligand 1 (PD-L1) inhibitors being the most studied drugs.
P. Tomasini, L. Greillier, Arnaud Boyer, Arnaud Jeanson, F. Barlesi   +4 more
semanticscholar   +1 more source

Cell‐free DNA aneuploidy score as a dynamic early response marker in prostate cancer

Molecular Oncology, EarlyView.
mFast‐SeqS‐based genome‐wide aneuploidy scores are concordant with aneuploidy scores obtained by whole genome sequencing from tumor tissue and can predict response to ARSI treatment at baseline and, at an early time point, to ARSI and taxanes. This assay can be easily performed at low cost and requires little input of cfDNA. Cell‐free circulating tumor
Khrystany T. Isebia, Anouk C. de Jong, Lisanne F. van Dessel, Vanja de Weerd, Corine Beaufort, Jean Helmijr, José Alberto Nakauma‐González, Job van Riet, Paul Hamberg, Daniel Vis, Michiel S. van der Heijden, Nick Beije, Martijn P. Lolkema, Teoman Deger, Saskia M. Wilting, Ronald de Wit, Maurice P. H. M. Jansen, John W. M. Martens   +17 more
wiley   +1 more source

Expression and Clinical Significance of LC-3 and P62 
in Non-small Cell Lung Cancer

Chinese Journal of Lung Cancer, 2018
Background and objective LC-3 and P62, two of important autophagy-related proteins, were reported highly expressed in many kinds of human malignancies and associated with outcomes of the patients.
Cong WANG, Yongwen LI, Ying LI, Hao GONG, Hongbing ZHANG, Yin YUAN, Weiting LI, Hongyu LIU, Jun CHEN   +8 more
doaj   +1 more source

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.

New England Journal of Medicine, 2002
BACKGROUND We conducted a randomized study to determine whether any of three chemotherapy regimens was superior to cisplatin and paclitaxel in patients with advanced non-small-cell lung cancer.
J. Schiller, D. Harrington, C. Belani, C. Langer, A. Sandler, J. Krook, Junming Zhu, David H. Johnson   +7 more
semanticscholar   +1 more source

Integration of single‐cell and bulk RNA‐sequencing data reveals the prognostic potential of epithelial gene markers for prostate cancer

Molecular Oncology, EarlyView.
Prostate cancer is a leading malignancy with significant clinical heterogeneity in men. An 11‐gene signature derived from dysregulated epithelial cell markers effectively predicted biochemical recurrence‐free survival in patients who underwent radical surgery or radiotherapy.
Zhuofan Mou, Lorna W. Harries
wiley   +1 more source

Using Apple Machine Learning Algorithms to Detect and Subclassify Non-Small Cell Lung Cancer [PDF]

arXiv, 2018
Lung cancer continues to be a major healthcare challenge with high morbidity and mortality rates among both men and women worldwide. The majority of lung cancer cases are of non-small cell lung cancer type. With the advent of targeted cancer therapy, it is imperative not only to properly diagnose but also sub-classify non-small cell lung cancer. In our
arxiv  

MET variants with activating N‐lobe mutations identified in hereditary papillary renal cell carcinomas still require ligand stimulation

Molecular Oncology, EarlyView.
MET variants in the N‐lobe of the kinase domain, found in hereditary papillary renal cell carcinoma, require ligand stimulation to promote cell transformation, in contrast to other RTK variants. This suggests that HGF expression in the microenvironment is important for tumor growth in such patients. Their sensitivity to MET inhibitors opens the way for
Célia Guérin, Audrey Vinchent, Marie Fernandes, Isabelle Damour, Agathe Laratte, Rémi Tellier, Gabriella O. Estevam, Jean‐Pascal Meneboo, Céline Villenet, Clotilde Descarpentries, James S. Fraser, Martin Figeac, Alexis B. Cortot, Etienne Rouleau, David Tulasne   +14 more
wiley   +1 more source